Ripretinib Versus Sunitinib in Patients With Advanced Gastrointestinal Stromal Tumor After Treatment With Imatinib (INTRIGUE): A Randomized, Open-Label, Phase III Trial.

doi:10.1200/JCO.22.00294

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Ripretinib Versus Sunitinib in Patients With Advanced Gastrointestinal Stromal Tumor After Treatment With Imatinib (INTRIGUE): A Randomized, Open-Label, Phase III Trial.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology - 1 Dec 2022

Bauer Sebastian, Jones Robin L, Blay Jean-Yves, Gelderblom Hans, George Suzanne, Schöffski Patrick, von Mehren Margaret, Zalcberg John R, Kang Yoon-Koo, Razak Albiruni Abdul, Trent Jonathan, Attia Steven, Le Cesne Axel, Su Ying, Meade Julie, Wang Tao, Sherman Matthew L, Ruiz-Soto Rodrigo, Heinrich Michael C

Abstract excerpt

PURPOSE: Sunitinib, a multitargeted tyrosine kinase inhibitor (TKI), is approved for advanced gastrointestinal stromal tumor (GIST) after imatinib failure. Ripretinib is a switch-control TKI approved for advanced GIST after prior treatment with three or more TKIs, including imatinib. We compared efficacy and safety of ripretinib versus sunitinib in patients with advanced GIST who were previously treated with...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Drug Resistance, Neoplasm

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Gastrointestinal Stromal Tumors

Share to Imatinib Mesylate

Share to Indoles

Share to Protein Kinase Inhibitors

Share to Proto-Oncogene Proteins c-kit

Share to Pyrroles

Share to Sunitinib

Source

Open in PubMed Open full text

Identifiers

PMID: 35947817
DOI: 10.1200/JCO.22.00294
PMCID: PMC9746771

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Ripretinib Versus Sunitinib in Patients With Advanced Gastrointestinal Stromal Tumor After Treatment With Imatinib (INTRIGUE): A Randomized, Open-Label, Phase III Trial.PMID 35947817Read ↗

Intrigue: Phase III study of ripretinib versus sunitinib in advanced gastrointestinal stromal tumor after imatinib.Semantic proximity Read ↗

Ripretinib for the treatment of adult patients with advanced gastrointestinal stromal tumors.Semantic proximity Read ↗

The INSIGHT study: a randomized, Phase III study of ripretinib versus sunitinib for advanced gastrointestinal stromal tumor with KIT exon 11 + 17/18 mutations.Semantic proximity Read ↗

An updated review of the treatment landscape for advanced gastrointestinal stromal tumors.Semantic proximity Read ↗

The multifaceted landscape behind imatinib resistance in gastrointestinal stromal tumors (GISTs): A lesson from ripretinib.Semantic proximity Read ↗

Clinical Activity of Ripretinib in Patients with Advanced Gastrointestinal Stromal Tumor Harboring Heterogeneous KIT/PDGFRA Mutations in the Phase III INVICTUS Study.Semantic proximity Read ↗

Ripretinib versus sunitinib in gastrointestinal stromal tumor: ctDNA biomarker analysis of the phase 3 INTRIGUE trial.Semantic proximity Read ↗

Emerging drugs for the treatment of gastrointestinal stromal tumors.Semantic proximity Read ↗

Ripretinib in advanced gastrointestinal stromal tumors: an overview of current evidence and drug approval.Semantic proximity Read ↗

New Tyrosine Kinase Inhibitors for the Treatment of Gastrointestinal Stromal Tumors.Semantic proximity Read ↗

Gastrointestinal Stromal Tumors: What Is the Best Sequence of TKIs?Semantic proximity Read ↗

Systemic therapy of advanced/metastatic gastrointestinal stromal tumors: an update on progress beyond imatinib, sunitinib, and regorafenib.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.